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Abstract
Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease of the joints affecting 1% of the world
population. It has major impact on patients through disability and associated comorbidities. Current treatment
strategies have considerably improved the prognosis, but recent innovations (especially biologic drugs and the new
class of so-called “JAK/STAT inhibitors”) have important safety issues and are very costly. Glucocorticoids (GCs) are
highly effective in RA, and could reduce the need for expensive treatment with biologic agents. However, despite
more than 65 years of clinical experience, there is a lack of studies large enough to adequately document the
benefit/harm balance. The result is inappropriate treatment strategies, i.e. both under-use and over-use of GCs,
and consequently suboptimal treatment of RA.
Methods: The GLORIA study is a pragmatic multicentre, 2-year, randomised, double-blind, clinical trial to assess
the safety and effectiveness of a daily dose of 5 mg prednisolone or matching placebo added to standard of care
in elderly patients with RA. Eligible participants are diagnosed with RA, have inadequate disease control (disease
activity score, DAS28 ≥ 2.6), and are ≥ 65 years. The primary outcome measures are the time-averaged mean value
of the DAS28 and the occurrence of serious adverse events or adverse events of special interest. During the trial,
change in antirheumatic therapy is permitted as clinically indicated, except for GCs. Cost-effectiveness and
cost-utility are secondary outcomes. The main challenge is the interpretation of the trial result with two primary
endpoints and the pragmatic trial design that allows co-interventions. Another challenge is the definition of safety
and the relative lack of power to detect differences between treatment groups. We have chosen to define safety
as the number of patients experiencing at least one serious adverse event. We also specify a decision tree to guide
our conclusion on the balance of benefit and harm, and our methodology to combat potential confounding
caused by co-interventions.
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Discussion: Pragmatic trials minimise impact on daily practice and maximise clinical relevance of the results, but
analysis and interpretation of the results is challenging. We expect that the results of this trial are of importance for
all rheumatologists who treat elderly patients with RA.
Trial registration: ClinicalTrials.gov, NCT02585258. Registered on 20 October 2015.
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Background
Rheumatoid arthritis (RA) is a systemic, chronic inflam-
matory disease mainly characterised by cartilage and
bone damage, progressive disability, decreasing quality
of life (QoL) and premature death [1]. Both the disease
and its treatment cause multiple comorbidities such as
increased incidence of cardiovascular disease, diabetes
mellitus, and osteoporotic fractures [1, 2]. Approxi-
mately 1% of the world population is affected by RA
with a prevalence of 2% in people 60 years and older [3].
In Europe, the prevalence of RA is expected to increase
along with the increase in the proportion of elderly in
the population. Current treatment strategies have con-
siderably improved the prognosis, but recent treatment
innovations (especially biologic drugs and JAK/STAT in-
hibitors) have important safety issues and come at high
societal cost [2, 4]; in addition, many patients still have
smoldering progressive disease despite treatment [2].
Apart from treatment, societal costs are a result of func-
tional disability, decreased societal participation, and re-
duced work capacity [1].
Balance of benefit and harm of glucocorticoid treatment
Glucocorticoids (GC) exhibit unparalleled anti-
inflammatory and immunosuppressive actions. The
introduction of GCs in the 1950s was a revolution in
the treatment of inflammatory diseases, including RA;
it resulted in the only Nobel Prize awarded to a
rheumatologist (Hench, together with Kendall and
Reichstein in 1950). In those early years, enthusiasm
generated by the initial results of unequalled efficacy in
previously untreatable diseases led to the unrestricted
use of high doses of GC. Unfortunately, such use dis-
closed a spectrum of adverse events that caused wide
disillusionment and a still ongoing debate about the
balance between the benefit and harm of GC treatment.
Recent trials have suggested this balance can be
favourable [5, 6]. In addition, a meta-analysis has
proven beyond doubt that GCs at low doses slow the
progression of joint damage in RA [7]. These findings
have renewed and induced both European and US
rheumatology associations to review their position, es-
pecially in early RA [8, 9]. Low-dose GCs (defined as a
daily dose of 7.5 mg prednisolone equivalent or less)
could prove an important co-treatment of both early
and established RA in combination with other anti-
rheumatic drugs. Apart from their clinical effects, low-
dose GCs have the potential to reduce the need for
expensive biologic agents. Unfortunately, clinical stud-
ies large enough to adequately document the long-term
balance of benefit and harm of low-dose GCs are lack-
ing. A limited set of high quality data from trials does
not support strong claims of harm (as opposed to a
wealth of observational studies with high potential for
bias), but the generalizability of trial data is questioned
[10]. The result is inappropriate treatment strategies
associated with both under-use and over-use of GCs,
and consequently suboptimal treatment of chronic in-
flammation in RA [11].
Adherence
Medication adherence (or compliance; generally defined
as the extent to which patients take medications as pre-
scribed) is often below 50% in patients with chronic dis-
eases such as RA [12]. The measurement of medication
adherence in clinical trials is challenging, and many dif-
ferent methods have been tried [13]. Computerised de-
vices or electronic monitoring devices assess adherence
more accurately than self-reporting and prescription re-
fill records. Linking electronic monitoring devices to
apps on smart devices may improve adherence.
The trial
This report describes the design of the Glucocorticoid
Low-dose Outcome in Rheumatoid Arthritis (GLORIA)
study, which compares the balance of benefit and harm
of the addition of 5 mg/day prednisolone or placebo to
standard of care for 2 years, in patients 65 years of age
and older. A secondary objective is to study adherence
and to test the effectiveness of smart device technology
to improve adherence in a randomised sub-study. The
report focuses on the occurrence and influence of co-
treatment as a result of the pragmatic design and the in-
terpretation of the outcomes of benefit and harm. The
details of the sub-study about adherence are described
in Additional file 1. The items addressed in this protocol
are described in the standard protocol items: recommen-
dation for interventional trials (SPIRIT) checklist in
Additional file 2.
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Cost-effectiveness
Another aim of this trial is to study the cost-effectiveness
and cost-utility of adding low-dose glucocorticoid to the
treatment of patients with RA. The costs of current RA
treatment are very high with mean costs estimated at
€3000/patient/year, and €15.0000/patient/year for patients
on biologic treatment [14]. Significant savings can be rea-
lised by improving the RA treatment strategy [14]. It is
very likely that the optimised use of GCs in RA would
allow for important savings, specifically by delaying or
avoiding the need for expensive biologic drugs and other
agents such as JAK/STAT inhibitors.
Methods
Study design
The GLORIA study is a randomised, double-blind,
placebo-controlled pragmatic multicentre clinical trial
(phase IV). Eight hundred patients with RA are planned
to be recruited from rheumatology clinics in seven
European countries: Germany, Hungary, Italy, the
Netherlands, Portugal, Romania, and Slovakia.
Patients will be randomised to either prednisolone or
matching placebo in a 1:1 ratio. Randomisation is strati-
fied for participating study site, for prior exposure to GC,
and for concurrent start or change of any other second-
line antirheumatic therapy. The randomisation is inte-
grated in an interactive web response system (IWRS) as
part of the electronic data management system. The mini-
misation randomisation method [15] will be used. Mini-
misation is a method of randomisation that allocates
subjects to the treatment group that best maintains bal-
ance in stratifying factors. It is effective even at small sam-
ple sizes and with multiple stratification variables [16].
Eligibility criteria
The eligibility criteria are shown in Table 1.
Inclusion criteria: patients diagnosed with RA (1987
[17] or 2010 criteria [18]), inadequate disease control
(disease activity score in 28 joints (DAS28) ≥ 2.6) [19],
and age 65 years or older.
Exclusion criteria: these criteria are categorised as having
low probability of benefit, having high probability of harm,
difficulty in measuring benefit and/or harm, and patients
not capable of or willing to provide informed consent.
Intervention
Patients will receive either prednisolone 5 mg/day or
matching placebo added to existing antirheumatic treat-
ment, for 2 years. Subsequently, study medication is
slowly tapered in linear fashion to zero over 3 months
by inserting increasing numbers of non-treatment days
every 2 weeks (first 2 weeks, no capsule on Mondays;
second 2 weeks, no capsule on Monday and Thursdays,
etc.). As in standard of care, all patients will receive daily
calcium 500 mg and vitamin D3 800 IU. Dietary or life-
style requirements will not be imposed upon patients be-
cause this is not done in standard care.
Patients may suffer from partial or complete unre-
sponsiveness of the hypothalamic-pituitary-adrenal
(HPA) axis in times of stress. Therefore, the following
procedure is followed to prevent medical complications.
No action is required for patients with minimal stress.
Table 1 Inclusion and exclusion criteria for participating in the
GLORIA trial
Inclusion criteria
1. Diagnosed with RA according to the 1987 or 2010 classification
criteria of the American College of Rheumatology (ACR) and the
European League Against Rheumatism (EULAR) [17, 18]
2. Inadequate disease control, as evidenced by a disease activity
score of 28 joints (DAS28) ≥ 2.6, calculated with erythrocyte
sedimentation rate
3. Age ≥ 65 years
Exclusion criteria
1. Having low probability of benefit
a. Change, stop or start of antirheumatic treatment in the last
month prior to eligibility assessment, including methotrexate,
sulfasalazine, hydroxychloroquine, leflunomide, azathioprine,
intramuscular and oral gold, cyclosporine, biologic agents
including anti-tumour necrosis factor (TNF), anakinra, abatacept,
rituximab, tocilizumab
b. Treatment with systemic glucocorticoid (GC): oral or parenteral
GC with a cumulative prednisolone equivalent dose of 200 mg
or higher in the last 3 months.
c. Treatment with any GC (oral, intra-articular, intravenous
or intramuscular) in the last 30 days
2. Having high probability of harm
d. Exposure to investigational therapy in the last 3 months
e. Current participation in another clinical trial
f. Major surgery, donation, or loss of approximately 500 ml
blood within 4 weeks prior to the screening visit
g. Absolute contraindication to low-dose prednisolone, as
determined by the treating physician, such as: uncontrolled
chronic infections, diabetes mellitus, hypertension, osteoporosis.
When these conditions are under control
(e.g. with anti-osteoporosis drugs, antihypertensive drugs) these
patients can enter
h. Absolute contraindication to calcium and/or vitamin D
supplement as determined by the treating physician,
such as hyperparathyroidism (when insufficiently treated)
i. Uncontrolled comorbidities, short life span, etc. as determined
by the treating physician
3. Difficulty in measuring benefit/harm
j. Absolute indication to start with oral or intravenous GC,
according to the treating physician
k. Inability to comply with medical instructions or inability to assess
major outcomes
4. Not capable or willing to provide informed consent
Most exclusion criteria are temporary
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Patients with mild stress will take one extra capsule of
study medication for 1–2 days. Patients with moderate
stress (i.e. surgical procedures, infections requiring par-
enteral antibiotics) will receive 25 mg hydrocortisone
directly before the procedure and 8-hourly thereafter for
1–2 days or until recovery. Study medication can be
restarted when the patient is back on oral feeding. For
patients with severe stress, the same procedure as for
patients with moderate stress is followed, except that pa-
tients with severe stress will be treated with 50 mg
hydrocortisone. Patients do not need to be unblinded to
treatment allocation if not required. They can restart
study medication after the stress period has ended.
Use of co-interventions for the treatment of RA
Apart from the study medication all other treatment, ex-
cept oral and intravenous GCs, is allowed; both treat-
ment for comorbidities and antirheumatic treatment are
allowed at the discretion of the treating physician. This
includes biologic and non-biologic disease-modifying
antirheumatic drugs (DMARDs), non-steroidal anti-
inflammatory drugs (NSAIDs), acetaminophen, and
short-term GC for comorbidities (e.g. chronic obstruct-
ive pulmonary disease). Patients requiring short-term
oral GC for comorbidities can also stay in the study;
such patients will continue to use study medication and
will follow the normal assessment schedule.
To approach an initial “clean comparison” between
treatment arms it is advised not to start other antirheu-
matic therapy (DMARDs, biologic drugs, etc.) or give
intramuscular (i.m.) or intra-articular (i.a.) GC injec-
tions in the first 3 months. However, it is allowed if
clinically judged as unavoidable. In such cases, pre-
ferred administration is at baseline. Patients developing
an absolute indication for oral or intravenous GC ther-
apy for their RA will discontinue the study drug, but
will be retained in follow up and handled separately in
the analysis. Patients undergoing emergency or routine
surgery can be unblinded if parenteral GC is needed
perioperatively. In the case of elective surgery, study
medication can be given perioperatively as oral GC for
adrenal crisis prophylaxis if local guidelines permit,
thus obviating the need for unblinding.
Adherence
To measure adherence, an adherence medication pack-
aging solution that combines objective therapy compli-
ance monitoring technology and special software is
delivered. All patients will have an adherence monitoring
device loaded into the cap of the drug bottle. Caps will be
collected and sent back to the manufacturer to be read
centrally. Adherence data on all patients will be registered
in the study database and analysed at the end of the study.
In a sub-study an intervention to improve adherence will
be tested (see Additional file 1).
Study medication
Prednisolone 5 mg is bought commercially, and tablets
of equal weight are manufactured; both are over-
encapsulated to create the blinded study medication.
These processes are performed by Bluepharma – Indús-
tria Farmacêutica, S.A., which is located in Coimbra,
Portugal, under Good Manufacturing Practice guide-
lines. Subsequently, Bluepharma ships the medication in
controlled batches to each clinical site pharmacy, where
it is securely stored in the original package under con-
trolled conditions.
The local pharmacy supplies the study medication to
the patients. At each visit, patients return their medica-
tion bottle and remaining capsules; the procedure, in-
cluding capsule count, is logged.
Procedures
Assessments comprise seven clinic visits and three as-
sessments by telephone. Assessments include the collec-
tion of demographic and clinical data, through physical
examination and questionnaires (Fig. 1). Almost all as-
sessments (and their frequency) are routine and can be
regarded as standard of care. The assessments are repre-
sented in the SPIRIT table in Fig. 1.
Outcomes
Outcomes and variables will be collected at baseline and
3-monthly thereafter. After 2 years, trial medication will
be tapered and stopped over 3 months.
Primary outcome measures
Benefit Benefit will be measured on disease activity, i.e.
time-averaged mean value of the Disease Activity Score
of 28 joints (DAS28) and on progression of joint dam-
age. The DAS28 is an index calculated from counts of
painful and swollen joints (28 joints, i.e. shoulders, el-
bows, wrists, metacarpophalangeal and proximal inter-
phalangeal joints, and knees), erythrocyte sedimentation
rate and patient global assessment [19]. The DAS28 will
be performed at all clinic visits, except for the baseline
and the 2-year visit. During these two visits a more com-
prehensive DAS of 44 joints (DAS44) will be performed
[19]. Damage progression is measured by 2-year change
in total Sharp/van der Heijde damage score assessed on
radiographs of the hands and forefeet [20].
Harm Contrary to most drug trials, GLORIA designates
harm as a co-primary outcome because the intake of
prednisolone is driven mostly by perceptions of harm.
Assessing harm in trials is challenging because the
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Fig. 1 SPIRIT figure
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incidence of serious adverse events (SAEs) is usually
rare, leading to power issues [21]. As clinical concern
about the use of GCs relates to many different events,
we decided to create a composite definition of harm,
comprising the number of patients with at least one SAE
or an adverse event (AE) deemed of special interest (de-
fined below). We expect the proportion of patients
meeting this definition to be about 20% in the control
group, which allows detection of meaningful differences
with the GC group at the chosen sample size.
Harm will be evaluated by spontaneous descriptions of
the patient or physician, and by the results of a 53-item
symptom list completed by the patients at the beginning
and end of the study. AEs deemed of special interest are
defined as follows:
 Any AE (except loss of efficacy, worsening of
disease) that leads to the definite cessation of one of
the antirheumatic drugs, including trial medication
 Cardiovascular event (myocardial infarction,
cerebrovascular event, peripheral arterial vascular event)
 Newly occurring hypertension requiring drug
treatment
 Newly occurring diabetes mellitus requiring drug
treatment
 Symptomatic bone fracture requiring treatment
 Infection requiring antibiotic treatment
 Newly occurring cataract or glaucoma
Where appropriate, both incidence rates of SAEs
and AEs of special interest and sufficient detail on
the clinical characteristics of SAEs and AES, such as
severity, frequency, and timing, will be reported [22].
AEs of special interest will be adjudicated by requir-
ing a declaration from the site physician, backed up
by source documentation on site (e.g. correspondence
on hospital admission).
Secondary outcome measures
Demographic measurements, medical history, and prog-
nostic factors (including risk factors for glaucoma,
education, adherence, health literacy and arthritis help-
lessness index) are assessed at baseline.
Cost data will be collected by a cost-questionnaire com-
pleted 3-monthly. For cost items, unit prices calculated in
previous studies and tariffs will be used. Costs that will be
estimated are direct health care costs (i.e. costs of treat-
ment and monitoring, including prevention and treatment
of side effects) and indirect costs (based on activity limita-
tions valued at shadow price for patients not working, and
work disability for those still holding a paid job). Produc-
tion losses will be valued using the friction cost method:
only sick leave during a friction period (23 weeks) needed
to replace a person is taken into account.
Secondary outcome measures regarding benefit and
harm of prednisolone or placebo include the World
Health Organization-International League of Associa-
tions for Rheumatology (WHO-ILAR) core set of RA
outcome measures [23], morning stiffness, fatigue, bone
mineral density and vertebral fractures. For a full listing
see Additional file 3.
Medical emergencies
Each randomised subject will be provided with a card
detailing emergency contact details. Subjects will be re-
quested to carry this card with them at all times whilst
participating in the trial. In the case of emergency and if
clinically necessary, the study team can contact the un-
blinded reviewer to break the code.
The Sponsor has clinical trial insurance, which is in
accordance with relevant legislation in the participating
countries. A patient will receive appropriate compensa-
tion in the case of any injury caused by participation in
the trial. The insurance applies to damage that becomes
apparent during the study or within 4 years after the end
of the study.
Data management and monitoring
During the study, clinical trial management and moni-
toring is performed by a clinical research organisation.
The information required by the protocol is entered into
an electronic data collection system. Plausibility checks
will be performed according to a data validation plan.
After all data are entered and all queries are resolved,
the database will be closed.
Sample size calculation
In the chosen analysis strategy, to detect differences in
benefit (disease activity), extensive RA trial experience
(both for GC and other agents) has shown a sample size
of 200 patients per group is amply sufficient [5]. For harm,
the true incidence of AEs with GC treatment is currently
unknown. Most relevant data to assess sample size ad-
equacy for this study come from the CAMERA-2 trial [6].
Based on a one-sided Z test, at a base case expectation
for a total of 20% of patients experiencing at least one
event in 2 years in the placebo group and 400 patients
in each treatment group, we have about 80% power to
detect an increase of 7% (from 20 to 27% events; 90%
power for an increase of 9%). These estimates change lit-
tle when the base case expectation is varied by ± 5%.
At the chosen sample size, and observed placebo event
rates between 15 and 25%, observed point estimates of
difference of 4–5%, respectively, will have a one-sided p
value < 0.05 and thus be declared significant. In case the
trial detects smaller, non-significant differences in AEs
favouring placebo, the upper 95% confidence bound can
be calculated to be about 3–4% above the point estimate.
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For example, if the trial shows a non-significant differ-
ence of 3% more AEs in the GC group, this finding is
compatible with a real increase not exceeding 6%.
Statistical analyses
Hypotheses
We will test hypotheses about the differences in benefit
(DAS28 score and damage progression) and harm (en-
countering an adverse event, as defined in the protocol)
of prednisolone treatment versus placebo. We state two
sets of one-sided null hypotheses about treatment effects
of prednisolone, one set for benefit, the other for harm.
The hypotheses and their tests are one-sided in view of
pre-existing knowledge on benefit and harm.
Under the null hypothesis, we expect to find no differ-
ence in decrease in DAS28 and in joint damage progres-
sion between the prednisolone and the placebo group
after 2 years (primary benefit null hypothesis); and after
3 months (secondary benefit null hypothesis for DAS28).
Second, under the null hypothesis we expect to find no
difference in selected AEs (as defined in the protocol)
between the prednisolone and placebo group after 2 years
(primary harm null hypothesis) and 3 months (secondary
harm null hypothesis).
Harm and benefit analyses
We will estimate the average effect of treatment on con-
tinuous outcomes (e.g. DAS28 and on damage progres-
sion) in separate mixed-effects regression models [24].
We will apply a logistic mixed-effects regression model
to estimate the probabilities of harm and to test the dif-
ference in odds. In all models we account for the stratifi-
cation of the GLORIA design.
Quantifying the power of tests in mixed-effects models
is difficult as it is based on untestable assumptions. How-
ever, we expect that the mixed-effects models will increase
power over a simple Z test, discussed in the previous
section, due to the longitudinal structure of the data.
Primary analyses will be initially performed with the three
stratification factors and the interaction with treatment al-
location (country, prior GC exposure, change of antirheu-
matic treatment at baseline) in the model. Non-significant
factors will be excluded from subsequent models.
Missing data In the analysis with the first benefit out-
come of disease activity, operationalised as DAS28, we
first assume that missingness occurs at random [25].
The mixed-effect model will be estimated by full infor-
mation maximum likelihood [25], which assumes that
missingness can be explained by the observed data. In
addition, for dropouts we investigate the possibility that
missingness occurs not at random: we will do a worst-
case analysis where we assume that patients with miss-
ing DAS28 data after a certain date until the end of the
2-year trial period did not respond or lost response
(non-responder imputation). This imputation method
recodes the DAS28 value of all those missing assess-
ments to the patient’s baseline value.
The way of handling missing data for the second bene-
fit outcome of damage progression, operationalised as
difference between Sharp van der Heijde radiograph
scores at baseline and at 24 months, depends on which
value is missing. We will exclude patients with missing
data at both time points or at the 2 year measurement list-
wise from this analysis. In patients missing only a baseline
value, this value can be imputed by linear interpolation
from values of an older X-ray, if present; otherwise such
patients will also be excluded. In the second step, we will
extend the first analysis for a multiple imputation analysis
of missing outcomes using the algorithm “multiple imput-
ation by chained equations” (MICE) [26].
For the harm outcome, operationalised as the occur-
rence of at least one serious AE or an AE deemed of
special interest, for most dropouts from the study we
will have information to indicate the presence or ab-
sence of an AE at the last follow-up visit. If this informa-
tion is not present, we will first create a dataset under
the assumption that no such AE occurred in these cases
(best case analysis); and then we will create a dataset
under the assumption that such an AE did occur in
these cases (worst case analysis).
Classification of co-interventions Given that GLORIA
is a pragmatic trial where co-interventions are allowed,
the observed effects are likely a compound of the “pure”
treatment effects and the effects of (potentially differen-
tial) co-interventions in the treatment and placebo
groups. In theory, two types of confounding can be
distinguished - harm and benefit confounding. Harm
confounding does not play a role.
Benefit confounding can be defined as the expectation
that patients on placebo more frequently require co-
interventions because their RA is not under control,
leading to subsequent improvement in disease activity.
Benefit confounding will most likely work in one direc-
tion: it will decrease the difference in DAS28 or damage
progression between the prednisolone group and the
placebo group; so if the trial shows that the prednisolone
group has significantly more DAS28 improvement and
less damage progression (primary objective), benefit con-
founding no longer impacts the main conclusion of the
trial. If the primary objective is not met we will proceed
to assess the presence of benefit confounding. First, we
will study co-medication changes and distinguish three
types: (co-medication) intensification, switch and taper.
This forms the basis of a decision tree (Fig. 2).
The first type, permanent or temporary intensification
of co-medication, comprises an increased dose of current
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antirheumatic drug(s), the addition of a new antirheu-
matic drug to the current treatment, or an i.m. or i.a. GC
injection (Fig. 2, Box 1). In the case of intensification, lack
of efficacy can always be assumed.
The second type, co-medication switch, can be for lack
of efficacy or for an AE, as documented by a high
DAS28 or an AE report (Fig. 2, Box 2). The medical
monitor will adjudicate situations where neither of these
can be documented.
The third type, co-medication taper, comprises a de-
crease in dose or stop of current medication(s) with-
out initiating other antirheumatic therapy. The main
reason to taper is low disease activity, sometimes in
the presence of an AE (Fig. 2, Box 3). The medical
monitor will adjudicate situations where neither of
these can be documented.
For practical reasons the analyses regarding benefit
confounding are limited to the first “medication change
event” in the case of multiple events in the same patient.
If significantly more treatment intensifications, more
switches for lack of efficacy or fewer tapers for low dis-
ease activity occur in the placebo group than in the
prednisolone group, we will assume benefit confounding.
As we assume that benefit confounding works in one
direction, we will use one-sided log likelihood ratio tests
for differences in the occurrences of the three types of
co-medication changes (intensification, taper and switch)
between the prednisolone and placebo group.
If there are no differences between the groups in co-
medication changes we will proceed to the next step. This
is to study the 3-month results in the subgroup of patients
who started only study medication at baseline, i.e. who
had no changes in co-medication at baseline or in the first
3 months. We will assume benefit confounding if two
conditions are met: (1) prednisolone benefits these
patients more than placebo, i.e. a significant difference in
ΔDAS28 over 3 months, and (2) this improvement in
disease activity is maintained in the remaining trial period,
i.e. mean DAS28 in the prednisolone group does not
deteriorate more than 0.6 between 3 and 24 months.
If these conditions are not met, we will proceed to the
final step. We will compare the number of GC injections
between the groups. If there are significantly more injec-
tions in the placebo group, we will assume benefit con-
founding. The presence of benefit confounding will be
used in our interpretation of overall trial results.
Interpretation rules The interpretation of the trial re-
sult with two primary endpoints is a challenge. In this
trial we want to summarize the results in one outcome
measure because both primary endpoints are equally im-
portant for the final assessment of the trial result.
Fig. 2 Decision tree for the assessment of benefit confounding in an individual patient
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Therefore, we defined a composite outcome measure,
which assesses the outcomes of benefit (disease activity
and damage progression) and harm simultaneously. We
will compare the prednisolone group to the placebo
group and we will interpret the results as presented in
Fig. 3.
For benefit, the trial is a success if the disease activity
and damage progression are both lower in the prednisol-
one group (see Fig. 3a). In addition, it is a success if
either disease activity or damage progression is lower in
the prednisolone group, in the presence of benefit
confounding. Finally, it is a potential success if only
benefit confounding is demonstrated. For harm the trial
is a success if the occurrence of AEs is the same or
lower in the prednisolone compared to the placebo
group (see Fig. 3b).
The assessment of benefit and harm are then com-
bined for a final assessment (see Fig. 3c). Success in
(potential) benefit and harm obviously translate into
overall success, whilst other combinations result in a
tradeoff or failure. We assess the final outcome as a
failure if both benefit and harm do not result in suc-
cess. The tradeoff assessment is defined as a failure in
(potential) benefit, whilst harm was assessed as a suc-
cess. The other possibility for tradeoff is a success in
(potential) benefit and a failure in harm.
Cost analyses
The analyses of cost will be driven by the primary ana-
lysis result and interpretation. If the combined assess-
ment of benefit and harm is a success (both benefit
and harm favour GC), cost-effectiveness analysis will
be performed with the mean DAS28 as the effective-
ness measure. If the combined assessment is a failure,
a simple cost comparison will be performed. Finally, if
the combined assessment points to a tradeoff, a cost-
utility analysis will be performed. The reason is that
there is no simple metric for effectiveness other than
the utility to describe the potential benefit of treatment
in this situation.
The cost analyses will be performed according to the
intention-to-treat principle and from a societal perspec-
tive. Analysis will involve models of cost per unit of ef-
ficacy. Different outcome measures will be used as unit
of efficacy. Confidence intervals (CI) for costs and dif-
ferences in costs will be estimated using bias-corrected
accelerated bootstrapping with 1000 iterations.
The incremental cost effectiveness ratio (ICER) will
be calculated by dividing the difference between the
mean costs by the difference in mean effects of the two
treatment groups. CIs for the ICER are also calculated
using bootstrapping with 5000 iterations. The results
will be graphically presented on the cost-effectiveness
plane and a cost-effectiveness acceptability curve will
be constructed. Sensitivity analysis will be done to as-
sess the effect of uncertainty in the main cost drivers
and utility estimates on the ICER.
(Serious) adverse events
Subjects will be carefully monitored throughout the
study for SAEs and suspected unexpected serious ad-
verse reactions (SUSARs). All SAEs and SUSARs will be
reported by the investigator to a pharmacovigilance
manager within 24 hours or 7 days of being aware of
them, respectively.
All SAEs and SUSARs that are possibly, probably or
definitely related to the investigational medical product
are subject to expedited reporting to regulatory author-
ities and ethics committees, in accordance with the
International Council on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for
Human Use (ICH) guidelines for Good Clinical Practice
(GCP) and the EU Directive 2001/20/EC and applicable
local regulations.
Discussion
We describe the protocol of the largest double-blind
clinical trial to date on the balance of benefit and harm
of adding low-dose GCs to the standard treatment of
RA. It is a pragmatic trial positioned in the elderly
where traditionally the evidence for treatment strat-
egies is limited. Since the eligibility criteria of our trial
are wide, we expect that many older patients with RA
are eligible to participate in the study. Also, our design
emulates the routine care setting. Assessments and
procedures are tailored to represent standard of care,
and concurrent antirheumatic treatment is allowed
next to the study medication with minimal limitations.
The design also creates challenges. We have chosen
harm as the co-primary outcome and tried to address
potential confounding due to co-interventions, result-
ing in an elaborate decision tree to best interpret the
results. Finally, we have tailored the cost analyses to
align with the possible result of the benefit-harm as-
sessment. The elderly population is also challenging to
study, given the comorbidity, co-medication and frailty
of these patients, increasing the chance of AEs and
premature drop-out, and complicating the analysis.
We expect that the results of this trial are of import-
ance for all rheumatologists who treat elderly patients
with RA, and most likely will result in adjustment of the
existing guidelines on RA treatment in elderly patients.
Trial status
Recruitment started in June 2016 and will last until
May 2018. This paper is based on protocol version 3.0
(18 May 2017).
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Fig. 3 Interpretation rules for the assessment of the benefit and harm outcomes: prednisolone versus placebo group. a Interpretation rules for
benefit: prednisolone versus placebo group. b Interpretation rules for harm: prednisolone versus placebo group. c Combined assessment for
benefit and harm: prednisolone versus placebo group
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